glioma
Pathos AI Closes $62M Series C Funding Round
The financing will allow the firm to further develop its AI platform, develop drugs in best responders, and acquire new pipeline candidates.
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.
FDA Approves Servier's Voranigo for Certain IDH-Mutated Gliomas
The approval marks the first targeted therapy commercially available for patients with grade 2 IDH-mutated glioma.
FDA Allowing Compassionate Use Access to Telix's Glioma PET Imaging Agent
Telix will seek FDA approval to sell TLX101-CDx as an imaging agent for advanced glioma patients.
Ipsen Licenses Day One's Ojemda Outside US in Deal Worth $461M
Ojemda was approved in the US earlier this year as a treatment for BRAF-altered pediatric low-grade glioma.
Dec 19, 2023
Mar 30, 2023